GBGB2018950.2A
GB202018950D0
(en)
|
2020-12-01 |
2020-12-01 |
Parenteral formulation
|
EP21720509.5A
EP3902541B1
(en)
|
2020-06-02 |
2021-04-23 |
Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
|
MX2022014900A
MX2022014900A
(en)
|
2020-06-02 |
2021-04-23 |
Deuterated compounds.
|
AU2021204158A
AU2021204158B2
(en)
|
2020-06-02 |
2021-04-23 |
Deuterated compounds
|
ES21720509T
ES2928395T3
(en)
|
2020-06-02 |
2021-04-23 |
Therapeutic compositions comprising deuterated or partially deuterated N,N-dimethyltryptamine compounds
|
CA3179161A
CA3179161C
(en)
|
2020-06-02 |
2021-04-23 |
Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
|
CN202180046463.XA
CN116056763B
(en)
|
2020-06-02 |
2021-04-23 |
Therapeutic compositions comprising deuterated or partially deuterated N, N-dimethyltryptamine compounds
|
PCT/EP2021/060750
WO2021116503A2
(en)
|
2020-06-02 |
2021-04-23 |
Deuterated compounds
|
PL21720509.5T
PL3902541T3
(en)
|
2020-06-02 |
2021-04-23 |
Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
|
NZ794833A
NZ794833A
(en)
|
2020-06-02 |
2021-04-23 |
Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
|
KR1020227045704A
KR102589605B1
(en)
|
2020-06-02 |
2021-04-23 |
Therapeutic composition comprising a deuterated or partially deuterated N,N-dimethyltryptamine compound
|
JP2022574099A
JP7288154B2
(en)
|
2020-06-02 |
2021-04-23 |
Therapeutic compositions containing deuterated or partially deuterated N,N-dimethyltryptamine compounds
|
IL298541A
IL298541B1
(en)
|
2020-06-02 |
2021-04-23 |
1,1-dideuterio-2-(1h-indol-3-yl)-n,n-bis(trideuteriomethyl)ethanamine and therapeutic composition comprising it
|
AU2021284861A
AU2021284861A1
(en)
|
2020-06-02 |
2021-05-13 |
Therapeutic solid dosage forms
|
GB2106881.2A
GB2595776B
(en)
|
2020-06-02 |
2021-05-13 |
Therapeutic solid dosage forms
|
EP21725377.2A
EP4149460A1
(en)
|
2020-06-02 |
2021-05-13 |
Therapeutic solid dosage forms
|
JP2022574098A
JP2023527575A
(en)
|
2020-06-02 |
2021-05-13 |
Therapeutic solid formulation
|
US17/320,155
US20210378969A1
(en)
|
2020-06-02 |
2021-05-13 |
Therapeutic solid dosage forms
|
CA3118556A
CA3118556A1
(en)
|
2020-06-02 |
2021-05-13 |
Therapeutic solid dosage forms
|
PCT/EP2021/062794
WO2021244831A1
(en)
|
2020-06-02 |
2021-05-13 |
Therapeutic solid dosage forms
|
IL298542A
IL298542A
(en)
|
2020-06-02 |
2021-05-13 |
Therapeutic solid dosage forms
|
CN202180046533.1A
CN115996713A
(en)
|
2020-06-02 |
2021-05-13 |
Therapeutic solid dosage forms
|
US17/458,167
US11471417B2
(en)
|
2020-06-02 |
2021-08-26 |
Deuterated N,N-dimethyltryptamine compounds
|
PCT/EP2021/083755
WO2022117640A1
(en)
|
2020-12-01 |
2021-12-01 |
Inhalable formulations
|
EP21816489.5A
EP4255421A1
(en)
|
2020-12-01 |
2021-12-01 |
Inhalable formulations
|
US18/252,949
US20240016782A1
(en)
|
2020-12-01 |
2021-12-01 |
Inhalable formulations
|